Advent-AWI Holdings Inc. announced that it has entered into a commercial agreement with DynoSense Corp. will sell and distribute certain health Products and Services in Hong Kong and Macau under a licence granted to it by DynoSense. DynoSense has created digital therapeutics which smartly apply clinical data technologies to modify behavior and improve health outcomes for its users. The Products and Services licenced to Advent and the HK Subsidiary are comprised of handheld health scanners which are wirelessly connected with cloud- based artificial intelligence via user-friendly and channel-customized software and mobile applications, which in turn are supported by personalized, care-centric services. The devices monitor certain vital signs and health conditions of the user (eg., heart rate, blood pressure, blood oxygen saturation levels, respiratory lung analysis, body temperature and body composition) and send the information via the cloud to the user's medical care professionals who are then able to read and interpret the user's medical information and from that provide advice and guidance to the user with respect to their medical condition at any given time. The Products and Services licenced to Advent and the HK Subsidiary include the products and technology described above as well as corresponding IT support services. It is a term of the Commercial Agreement that in the event the business is successful in the Territory, as reasonably determined by DynoSense, then DynoSense may grant Advent a priority over establishing a separate, but similar, arrangement in Canada for the purpose of conducting a business similar to the business in Hong Kong. Upon receipt of TSX Venture Exchange approval, Advent will proceed to incorporate the wholly-owned HK Subsidiary.